Q32 Bio Inc
q32bio.comQ32 Bio Inc (NASDAQ: QTTB) is a clinical-stage biopharmaceutical company that develops therapeutic product candidates targeting complement and other inflammatory pathways. The company does not generate product revenue and funds operations through capital raises, including equity issuances and convertible note conversions, as disclosed in its 10-K filed 2026-03-10. Its lead program, ADX-097, is licensed from The Regents of the University of Colorado and the Medical University of South Carolina under an exclusive, worldwide, royalty-bearing agreement entered in August 2017. Under that license, Q32 Bio has agreed to pay development and sales milestone payments of up to $2.2 million per licensed product for the first three products, tiered royalty rates on net sales in the low single-digit percentages, and 15% of certain sublicensing income. The company completed a reverse recapitalization merger in 2024, converting preferred stock to common stock and issuing shares to former Homology Medicines shareholders. As of December 31, 2025, accrued external research and development expenses totaled $0.5 million and prepaid external research and development expenses totaled $0.5 million.
Products & Services
ADX-097, a product candidate licensed from the University of Colorado and MUSC under an exclusive worldwide license, is the disclosed lead program. The company also operates an internal research platform focused on complement-mediated and inflammatory disease.
Revenue Model
Q32 Bio generates no product revenue as of the filing date. Operations are funded through equity capital raises. Future revenue, if any, would depend on milestone payments, royalties, or partnership agreements tied to clinical and regulatory progress.
Customers & Markets
Q32 Bio has no commercial customers as of the 10-K filed 2026-03-10. Target end markets are patients with complement-mediated or inflammatory diseases, including rare conditions with limited existing therapies.
Geographic Exposure
The Colorado License Agreement grants worldwide rights. The company references the EMA PRIME scheme, indicating awareness of European regulatory pathways, but no specific geographic revenue split is disclosed in the filing excerpts.
Financial Snapshot
Loading...
